Product Description
AMG 211 is a bispecific CEA-directed CD3 T-cell engager (BiTE(R)) that inhibits growth of CEA-expressing cancer cells in various cancer models. (Sourced from: https://www.annalsofoncology.org/article/S0923-7534(19)48893-5/fulltext)
Mechanisms of Action: BiTE,CD3 Inhibitor
Novel Mechanism: No
Modality: Bispecific Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Amgen
Company Location: THOUSAND OAKS CA 91320
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Adenocarcinoma
Phase 1: Adenocarcinoma|Gastrointestinal Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCT02291614 | P1 |
Terminated |
Adenocarcinoma |
2017-11-06 |
|
| 89Zr-AMG211 PET imaging study | P2 |
Terminated |
Adenocarcinoma |
2017-07-07 |
|
| NCT02760199 | P1 |
Completed |
Gastrointestinal Cancer |
2017-05-03 |
|
| MI-CP216 | P1 |
Completed |
Adenocarcinoma |
2015-01-01 |